JPRN-UMIN000013787已完成未知
Freqency of Carnitine Deficiency in Patients with Chronic Liver Disease, and Efficacy of Oral L-Carnitine Treatment for Patiens with Liver Cirrhosis - Freqency of Carnitine Deficiency in Patients with Chronic Liver Disease, and Efficacy of Oral L-Carnitine Treatment for Patiens with Liver Cirrhosis
Kansai Study Group of Liver Steatosis(KASALS)0 个研究点目标入组 80 人开始时间: 2014年4月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Pregnant and lactating females 2) Hisotry of drug allergy 3) Inappropriate for entry onto this study in the judgment of the investigator 4) Administration of other test drugs within 1 month
研究者
相似试验
尚未招募
Unknown
prevalence of heart related issues in patients admitted to intensive care unit having fever of less than 15 days of duration and having low blood pressureCTRI/2024/01/062067Kasturba Medical College Manipal
已完成
不适用
evothyroxine therapy in sub clinical hypothyroidismSubclinical Hypothyroidism.Subclinical iodine-deficiency hypothyroidismIRCT201103156027N1Endocrine and Metabolism research center of shahid Beheshti University of Medical Sciences30
进行中（未招募）
1 期
A study to investigate the effects of the drug derazantinib (formerly ARQ 087) in patients who have a type of bile duct cancer that cannot be operated on, or has spread, called Advanced Intrahepatic Cholangiocarcinoma. Patients will have a positive genetic test for FGFR2 Gene Fusion or FGFR2 gene mutations or amplifications.EUCTR2016-004448-12-GBBasilea Pharmaceutica International Ltd143
进行中（未招募）
1 期
A study to investigate the effects of the drug derazantinib (formerly ARQ 087) in patients who have a type of bile duct cancer that cannot be operated on, or has spread, called Advanced Intrahepatic Cholangiocarcinoma. Patients will have a positive genetic test for FGFR2 Gene Fusion or FGFR2 gene mutations or amplifications.Substudy 1Inoperable or advanced FGFR2 gene fusion positive iCCASubstudy 2:Inoperable or advanced iCCA harboring FGFR2 mutations or amplificationsMedDRA version: 20.0Level: LLTClassification code 10073077Term: Intrahepatic cholangiocarcinomaSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10073078Term: Intrahepatic cholangiocarcinoma recurrentSystem Organ Class: 100000004864EUCTR2016-004448-12-ESBasilea Pharmaceutica International Ltd147
招募中
不适用
Incidence of genetic abnormalities in patients with primary hypereosinophiliaThe patient 18 years and older ,The patients diagnosed with primary hypereosinophilia leukocyte count more than 1,500 per microliter for a period of more than 1 month.Incidence of genetic abnormalities in patients with primary hypereosinophilia.TCTR20210514006Siriraj Hospital Mahidol University151